+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 5 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are evaluating nipocalimab, a drug given intravenously or subcutaneously, for adults with generalized myasthenia gravis gMG, a condition causing muscle weakness. This Phase 3 study aims to compare the effectiveness and safety of nipocalimab against a placebo and to understand how the drug works in the body when given by injection under the skin versus through a vein. The study includes a subcutaneous substudy to explore these differences in delivery methods. Participants receive nipocalimab intravenous infusions every two weeks for up to 24 weeks during a double-blind placebo-controlled phase. Those completing this phase can enter an open-label extension, choosing to continue receiving intravenous nipocalimab or switch to the subcutaneous form given weekly for eight weeks, with the option to continue longer in a long-term extension. Placebo is also given intravenously every two weeks in the control group during the double-blind phase. Throughout the study, participants undergo regular assessments including muscle function scores, quality of life evaluations, and blood tests measuring antibody levels and drug concentration. Researchers monitor safety by tracking adverse events and changes in clinical and laboratory parameters. The study measures changes in activities of daily living related to myasthenia gravis over time. Participation may last several years, as long-term monitoring continues after the initial treatment phases to evaluate ongoing effects and safety.

Age: 18Years +All GendersPhase 3
112 locations
R

Actively Recruiting

Researchers are evaluating the efficacy, safety, and tolerability of ITI-1284, a sublingual drug, compared with placebo in treating psychosis associated with Alzheimers disease. This Phase 2, multicenter, randomized, double-blind, placebo-controlled study involves adults aged 55 and older diagnosed with Alzheimers disease and psychosis. The study aims to improve understanding of how ITI-1284 may affect psychotic symptoms in this population. Participants will receive either ITI-1284 tablets at doses of 10 mg or 20 mg or matching placebo tablets, taken once daily by sublingual administration. The study uses a flexible-dose design and follows a parallel-group model with random assignment to the drug or placebo groups. Treatment and assessments are conducted over the study period, with primary measurement of psychosis symptoms at Week 6. Throughout the trial, participants will be monitored regularly for symptom changes using the BEHAVE-AD psychosis subscale and the Clinical Global Impression-Severity score. Cognitive function will be evaluated using the Mini-Mental State Examination. Safety and tolerability will be assessed continuously, and a designated caregiver will support participants. The total study duration extends through to December 2028, with primary outcomes assessed at 6 weeks.

Age: 55Years +All GendersPhase 2
71 locations
M

Actively Recruiting

Researchers are conducting a master protocol consisting of three independent, multicenter, randomized, double-blind, placebo-controlled studies to evaluate ACP-204 in adults with Alzheimers Disease Psychosis ADP. The purpose is to assess the efficacy and safety of two doses of ACP-204 compared to placebo. The studies include a Phase 2 dose-response trial followed by two Phase 3 confirmatory trials, each analyzed separately. The research addresses the treatment of psychosis symptoms in adults aged 55 to 95 years with confirmed Alzheimers disease and psychosis. Participants receive either ACP-204 at 30 mg or 60 mg doses or a matching placebo once daily, approximately at the same time each day, with or without food. Each substudy includes a screening period lasting up to 49 days, a 6-week double-blind treatment period, and a 30-day safety follow-up for those not entering an open-label extension. Vital status follow-up is also conducted for participants who end the study early. During the study, participants undergo assessments including the Scale for the Assessment of Positive Symptoms-Hallucinations and Delusions subscales SAPS-HD and the Clinical Global Impression-Severity in the ADP context CGI-S-ADP. Study visits involve evaluation with a designated caregiver or study partner. Safety monitoring and vital status checks continue after treatment, with the total participation duration including screening, treatment, and follow-up periods.

Age: 55Years - 95YearsAll GendersPhase 2Phase 3
154 locations
S

Actively Recruiting

Researchers are studying the effects of a nutritional intervention combining ketogenic medium-chain triglycerides kMCT and B-vitamins on cognitive function in older adults diagnosed with mild cognitive impairment MCI. This randomized, double-blind, placebo-controlled trial aims to evaluate how this nutritional approach impacts cognitive performance over a 12-month period. The study is sponsored by Socit des Produits Nestl and involves multiple centers and countries. Participants will be randomly assigned to receive either BrainXpert, a dietary supplement containing 15 g of kMCT and B-vitamins in powder form, or a placebo consisting of a calorie-equivalent, non-ketogenic high-oleic acid sunflower oil powder. Both are provided in sachetstickpack format without preservatives, flavors, sweeteners, or colorants. The intervention is administered daily during the study period. During the trial, participants and their informants will attend clinic visits at baseline, 12 months, and 18 months. Cognitive function will be assessed using tools such as the Preclinical Alzheimers Cognitive Composite PACC, Montreal Cognitive Assessment MoCA, Wechsler Memory Scale, and Mini-Mental State Examination MMSE. Safety and tolerability will also be monitored throughout the 12 months. The study includes adherence assessments and requires participants to comply with study procedures and medication restrictions.

Age: 60Years +All GendersPhase Not Applicable
28 locations
E

Actively Recruiting

Researchers are evaluating the long-term clinical and instrumental response to Cardiac Contractility Modulation CCM therapy in adults with symptomatic heart failure caused by systolic left ventricular dysfunction despite adequate medical treatment. This observational cohort study, both retrospective and prospective, focuses on subjects already receiving CCM as part of their regular care. The study aims to assess clinical response, hospitalizations, quality of life, walking distance, and changes in heart biomarkers over 12 months. Participants carry the OPTIMIZER Smart Mini CCM device, a programmable implantable pulse generator connected to leads in the heart. The study groups are defined by their response to low-dose dobutamine stress echocardiography before implantation, with one group showing a reduction of 15% or more in left ventricular end-systolic volume LVESV and the other less than 15%. The low-dose dobutamine test involves incremental infusions of the drug to assess heart contractile reserve. During the 12-month follow-up, researchers will monitor changes in New York Heart Association NYHA class, hospitalizations, quality of life using the Minnesota Living with Heart Failure Questionnaire, walking test distance, and NT-proBNP biomarker levels. Additional assessments include echocardiographic measures and recording adverse events, cardiac device implants, or surgery. This comprehensive monitoring helps evaluate the clinical and functional effects of CCM therapy over time.

Age: 18Years +All Genders
13 locations